Novel actions of tyrphostin AG 879: Inhibition of RAF-1 and HER-2 expression combined with strong antitumoral effects on breast cancer cells

Cellular and Molecular Life Sciences

Volumn 61, Issue 19-20, 2004, Pages 2624-2631

  Larsson, L I ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

AG 879; Apoptosis; Breast cancer; Gene expression; HER 2; MAP kinase; Proliferation; RAF 1

Indexed keywords

3,5 DI TERT BUTYL ALPHA CYANO 4 HYDROXYTHIOCINNAMAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; TYRPHOSTIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN TARGETING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; PROTO-ONCOGENE PROTEINS C-RAF; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TIME FACTORS; TYRPHOSTINS;

EID: 9744285824     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-004-4279-5     Document Type: Article

References (47)

1. Blume-Jensen P. and Hunter T. (2001) Oncogenic kinase signalling. Nature 411: 355-365
2. Downward J. (2002) Targetting Ras signalling pathways in cancer therapy. Nat. Rev. Cancer 3: 11-22
3. Chen R.-H., Sarnecki C. and Blenis J. (1992) Nuclear localization and regulation of erk- and rsk-encoded protein kinases. Mol. Cell. Biol. 12: 915-927
4. Gonzalez F. A., Seth A., Raden, D. L., Bowman D. S., Fay F. S. and Davis J. R. (1993) Serum-induced translocation of mitogen-activated protein kinase to the cell surface ruffling membrane and the nucleus. J. Cell Biol. 122: 1089-1101
5. Lenormand P., Sardet C., Pages G., L'Allemain G., Brunet A. and Pouyssegur J. (1993) Growth factors induce nuclear translocation of MAP kinases (p42mapk and p44mapk) but not of their activator MAP kinase kinase (p45mapkk) in fibroblasts. J. Cell Biol. 122: 1079-1088
6. Cheng M., Sexl V., Sherr C. J. and Roussel M. F. (1998) Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase (MEK1). Proc. Natl. Acad. Sci. USA 95: 1091-1096
7. Lavoie J. N., L'Allemain G., Brunet A., Müller R. and Pouysségur J. (1996) Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/ HOGMAPK pathway. J. Biol. Chem. 271: 20608-20616
8. Weber J. D., Hu W., Jefcoat S. C. Jr, Raben D. M. and Baldassare J. J. (1997) Ras-stimulated extracellular signal-regulated kinase 1 and RhoA activities coordinate platelet-derived growth factor-induced G1 progression through the independent regulation of cyclin D1 and p27. J. Biol. Chem. 272: 32966-32971
9. Bonni A., Brunet A., West A.E., Datta S. R., Takasu, M. A. and Greenberg M. E. (1999) Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286: 1358-1362
10. Levitzki A. and Gazit A. (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267: 1782-1788
11. Levitzki A. (1990) Tyrphostins - potential antiproliferative agents and novel molecular tools. Biochem. Pharmacol. 40: 913-918
12. Buchdunger E., Matter A. and Druker B. J. (2001) Bcr-Abl inhibition as a modality of CML therapeutics. Biochim. Biophys. Acta 1551: M11-M18
13. Druker B. J. (2002) STI571 (Gleevec™) as a paradigm for cancer therapy. Trends Mol. Med. 8: S14-S18
14. Shawyer L. K., Slamon D. and Ullrich A. (2002) Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1: 117-123
15. Traxler P., Bold G., Buchdunger E., Caravatti G., Furet P., Manley, P. et al.. (2001) Tyrosine kinase inhibitors: From rational design to clinical trials. Med. Res. Rev. 21: 499-512
16. Yarden Y. and Sliwkowski M. X. (2001) Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2: 127-137
17. Bain J., McLauchlan H., Elliott M and Cohen P. (2003) The specificities of protein kinase inhibitors: an update. Biochem J 371:199-204
18. Houghton P. J., Germain G. S., Harwood F. C., Schuetz J. D., Stewart C. F., Buchdunger E. et al. (2004) Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res. 64:2333-2337
19. Buchdunger E., O'Reilly T. and Wood J. (2002) Pharmacology of imatinib (STI571). Eur J Cancer 38 (suppl 5): S28-36
20. Joensuu H., Roberts P. J., Sarlomo-Rikala M., Andersson L. C., Tervahartiala P., Tuveson D. et al. (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344: 1052-1056
21. Neckers L. (2002) Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 8: S55-S61
22. Schulte T. W. Blagosklonny M. V., Ingui C. and Neckers E. (1995) Disruption of the RAF-1-Hsp90 molecular complex results in destabilization of RAF-1 and loss of RAF-1-Ras association. J. Biol. Chem. 270: 24585-24588
23. Mimnaugh E. G., Chavanay C. and Neckers E. (1996) Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol. Chem. 271: 22796-22801
24. Ohmichi M., Pang L., Ribon V., Gazit A., Levitzki A. and Saltiel A. R. (1993) The tyrosine kinase inhibitor tyrphostin blocks the cellular actions of nerve growth factor. Biochemistry 32: 4650-4658
25. Nie Z., Mei Y., Malek R. L., Marcuzzi A., Lee N. H. and Ramkumar V. (1999) A role of p75 in NGF-mediated down-regulation of the A(2A) adenosine receptors in PC12 cells. Mol. Pharmacol. 56: 947-954
26. Xie Y., Tisi M. A., Yeo T. T. and Longo F. M. (2000) Nerve growth factor (NGF) loop 4 dimeric mimetics activate ERK and AKT and promote NGF-like neurotrophic effects. J. Biol. Chem. 275: 29868-29874
27. Piccinotti A., Benaglia G., Bresciani R., Zizioli D., Presta M., Preti A. et al. (2000) Nerve growth factor induces sphingomyelin accumulation in pheochromocytoma cells. FEBS Lett. 472: 143-147
28. Tsai S. Y., Chiu P. Y., Yang C. P. and Lee Y. H. (2002) Synergistic effects of corticosterone and kainic acid on neurite outgrowth in axotomized dorsal root ganglion. Neuroscience 114: 55-67
29. Rende M., Brizi E., Conner J., Treves S., Censier K., Provenzano C. et al. (2000) Nerve growth factor (NGF) influences differentiation and proliferation of myogenic cells in vitro via TrkA. Int. J. Dev. Neurosci. 18: 869-885
30. Yeh S., Lin H. K., Kang H. Y., Thin T. H., Lin M. F. and Chang C. (1999) From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. USA 96: 5458-5463
31. Meng T. C., Lee M. S. and Lin M. F. (2000) Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. Oncogene 19: 2664-2677
32. Venkateswarlu S., Dawson D. M., St Clair P., Gupta A., Willson J. K. and Brattain M. G. (2002) Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells. Oncogene 21: 78-86
33. Lee M. S., Igawa T., Yuan T. C., Zhang X. Q., Lin F. F. and Lin M. F. (2003) ErbB-2 siganling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells. Oncogene 22: 781-796
34. Grunt T. W. (2003) Tyrphostins and retinoids cooperate during inhibition of in vitro growth of ovarian cancer cells. Cancer Lett. 189: 147-156
35. He H., Hirokawa Y., Manser E., Lim L., Levitzki A. and Maruta H. (2001) Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases that block PAK activation. Cancer J. 7: 191-202
36. Mortensen K., Skouv J., Hougaard D. M. and Larsson L.-I. (1999) Endogenous endothelial cell nitric oxide synthase modulates apoptosis in cultured breast cancer cells and is transcriptionally regulated by p53. J. Biol. Chem. 274: 37679-37684
37. Denizot F. and Lang R. (1986) Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods 89: 271-277
38. Martin S. J., Reutelingsperger C. P., McGahon A. J., Rader J. A., Schie R. C. van, LaFace D. M. et al. (1995) Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med. 182: 1545-1556
39. Mortensen K. and Larsson L.-I. (2003) Effects of cytochalasin D on the actin cytoskeleton: association of neoformed actin aggregates with proteins involved in signaling and endocytosis. Cell. Mol. Life Sci. 60: 1007-1012
40. Favata M. F., Harinchi K. Y., Manos E. J., Daulerio A. J., Stradley D. A., Feeser W. S. et al. (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273: 18623-18632
41. Dieter M. Z., Freshwater S. L., Solis W. A., Nebert D. W. and Dalton T. P. (2001) Tyrphostin AG 879, a tyrosine kinase inhibitor: prevention of transcriptional activation of the electrophile and the aromatic hydrocarbon response elements. Biochem. Pharmacol. 61: 215-225
42. Roh H., Pippin J. and Drebin J. A. (2000) Downregulation of HER-2/neu expression induces apoptosis in human cancer cells that overexpress HER-2/neu. Cancer Res. 60: 560-565
43. Cupp A. S., Uzumcu M. and Skinner M. K. (2003) Chemotactic role of neurotrophin 3 in the embryonic testis that facilitates male sex determination. Biol. Reprod. 68: 2033-2037
44. Franco R., Torres-Marquez M. E. and Pasantes-Morales H. (2001) Evidence for two mechanisms of amino acid osmolyte release from hippocampal slices. Pflugers Arch. 442: 791-800
45. Konrad R. J., Dean R. M., Young R. A., Billings P. C. and Wolf B. A. (1996) Glucose-induced tyrosine phosphorylation of p125 in beta cells and pancreatic islets. a novel proximal signal in insulin secretion. J. Biol. Chem. 271: 24179-24186
46. Asslan R., Pradines A., Pratx C., Allal C., Favre G. and La Gaillard F. (1999) Epidermal growth factor stimulates 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression via the ErbB-2 pathway in human breast adenocarcinoma cells. Biochem. Biophys. Res. Commun. 260: 699-706
47. Carlson R. O. and Aschmies S. H. (1995) Tyrosine kinase activity is essential for interleukin-1 beta-stimulated production of interleukin-6 in U373 human astrocytoma cells. J. Neurochem. 65: 2491-2499